Beijing Centergate Technologies Holding Co Ltd

The company maintains a debt-to-equity ratio of 0.72, indicating a moderate reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 1.15, suggesting limited short-term liquidity cushion. Free cash flow stands at 87.9 million CNY, while operating cash flow is 41.6 million CNY, both of which are positive but relatively modest in scale. Profitability metrics show a return on equity (ROE) of 2.93% and a return on assets (ROA) of 1.2%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The operating margin is 4.37% (106.8 million CNY operating income on 2.44 billion CNY revenue), and the net margin is 1.96% (47.9 million CNY net income on 2.44 billion CNY revenue), indicating thin profitability. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to localized market risks. Revenue growth is not explicitly forecasted, but the company's capital expenditures of -99.9 million CNY suggest a reduction in investment in new capacity or infrastructure. This may indicate a strategic shift or financial constraint. The risk assessment highlights a medium liquidity risk and a low dilution risk. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints in the near term. No recent events or filings have been disclosed that would significantly alter the company's risk profile. The company's recent performance, as observed in IR data, shows a last actual EPS of 0.09 CNY and a last actual revenue of 1.997 billion CNY, both of which are in line with the disclosed financials.